Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m

NCT00136604 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

617

Enrollment

INDUSTRY

Sponsor class

Conditions

Whole Cell Pertussis
Haemophilus Influenzae Type b
Hepatitis B
Diphtheria
Tetanus
Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin

Interventions

BIOLOGICAL: Tritanrix-HepB/Hib-MenAC
BIOLOGICAL: Mencevax ACWY
BIOLOGICAL: Tritanrix-HepB/Hiberix
BIOLOGICAL: Meningitec

Sponsor

GlaxoSmithKline